Manufacturing News

Lotte nabs BMS facility in New York; Alcami acquisition complete – Endpoints News


Bris­tol My­ers Squibb is hand­ing over the keys to its man­u­fac­tur­ing site in Syra­cuse, NY, to South Ko­re­an com­pa­ny Lotte Bi­o­log­ics.

BMS an­nounced this week that the sale of the fa­cil­i­ty is com­plete, with its di­ves­ture from the Syra­cuse man­u­fac­tur­ing site a part of an ef­fort to “evolve” the phar­ma’s man­u­fac­tur­ing net­work. As part of the deal, all em­ploy­ees will con­tin­ue to work for Lotte. BMS has al­so en­tered in­to a con­tract with Lotte to con­tin­ue man­u­fac­tur­ing some of its prod­ucts at the fa­cil­i­ty.

Last year, South Ko­rea’s Yon­hap News Agency re­port­ed that the sale cost Lotte $160 mil­lion.

Mil­li­pore­Sig­ma, Mer­ck KGaA’s life sci­ence busi­ness in the US and Cana­da, will help Lotte in es­tab­lish­ing its man­u­fac­tur­ing ca­pa­bil­i­ties in the US as well as with de­sign and work­force train­ing at the site.

Ac­cord­ing to the lo­cal news site, Syra­cuse.com Lotte al­so plans to in­vest around $77 mil­lion to ex­pand its man­u­fac­tur­ing ca­pac­i­ty at the site.

Cap­i­tal firms close Al­ca­mi ac­qui­si­tion

Al­ca­mi, the North Car­oli­na-based CD­MO, has of­fi­cial­ly been ac­quired by two ven­ture cap­i­tal firms.

In the deal, of which terms were not dis­closed, GHO Cap­i­tal Part­ners and The Vis­tria Group se­cure the ac­qui­si­tion of Al­ca­mi from funds af­fil­i­at­ed with Am­per­sand Cap­i­tal Part­ners and Madi­son Dear­born Part­ners. Both GHO and Vis­tria have a 50/50 con­trol­ling in­ter­est in the CD­MO.

Al­ca­mi has five lo­ca­tions across the US and cur­rent­ly does con­tract­ing work in fill-fin­ish and sol­id-dose man­u­fac­tur­ing along with lab and stor­age ser­vices.

Poly­sciences in­tro­duces a new brand for bio­pro­cess­ing

The Penn­syl­va­nia-based chem­i­cals man­u­fac­tur­er Poly­sciences is plan­ning a new brand spe­cif­ic to its of­fer­ing for the bio­pro­cess­ing mar­ket.

Dubbed Ky­fo­ra Bio, the brand will fo­cus on the man­u­fac­ture of lipids, poly­mers and oth­er ma­te­ri­als that are used in cell and gene ther­a­pies. Ky­fo­ra Bio will al­so have its own fa­cil­i­ty in the town of Hor­sham, PA, out­side of Philadel­phia. The 45,000-square-foot site will have man­u­fac­tur­ing suites, of­fices and labs for qual­i­ty con­trol and Re­search and de­vel­op­ment.

“Ky­fo­ra Bio re­flects Poly­sciences’ lat­est com­mit­ment to be the part­ner of choice in sup­ply­ing key cGMP-com­pli­ant ma­te­ri­als to the cell and gene ther­a­py mar­ket,” Scott Knorr, pres­i­dent of Ky­fo­ra Bio, said in a state­ment.

Bruk­er nets ma­jor­i­ty own­er­ship of Swiss CRO

The Bruck­er cor­po­ra­tion has net­ted the ma­jor­i­ty own­er­ship of Biog­nosys for an undis­closed amount. The trans­ac­tion was not dis­closed, but sev­er­al in­vestors sold shares to Bruck­er in an­oth­er trans­ac­tion.

The deal in­cludes Bruk­er mak­ing new in­vest­ments in the Swiss com­pa­ny, with Biog­nosys CEO Oliv­er Rin­ner and the lead­er­ship team con­tin­u­ing to man­age the CRO. The deal will al­so give Biog­nosys a foot in the door to the US mar­ket and ac­cess to Bruk­er’s tech­nol­o­gy.

The part­ner­ship al­so in­cludes Biog­nosys plans to open a CRO lab­o­ra­to­ry in the US, al­though the lo­ca­tion and time­line have not been dis­closed.

Cur­rent­ly, Biog­nosys of­fers mass spec­trom­e­try-based re­search ser­vices fo­cus­ing on drug and pro­tein dis­cov­ery, among oth­er ser­vices.



Source link